{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:10:55Z","timestamp":1787890255246,"version":"build-2784847793"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Neurokinin 1 receptor antagonists included prophylactic treatment was recommended for patients who receive one-day cisplatin chemotherapy. It is unclear whether the prolonged administration of fosaprepitant is effective for three-day cisplatin-based chemotherapy induced nausea and vomiting (CINV). We aim to explore the prophylactic antiemetic efficacy and safety of two doses of fosaprepitant included regimen in the patients receiving multiple-day cisplatin chemotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This randomized, parallel-group, open-labelled study was conducted in nine hospitals between February 2021 and February 2023. Patients diagnosed as lung cancer and chemotherapy naive were screened. Eligible participants were scheduled to be treated with highly emetogenic chemotherapy regimen which including three days of cisplatin. Then they were randomly divided into the experimental group (two doses of fosaprepitant, Group 2DF) and the control group (one dose of fosaprepitant, Group C). The primary endpoints included the safety and the average none CINV days (NCDs). This study was registered on the website of chictr.org.cn, number ChiCTR2100042665.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 204 participants were randomly assigned, and 198 patients were analyzed. No statistical difference in adverse events was found between the two groups. All treatment-related adverse effects for fosaprepitant observed were of grade 1\u20132. The average NCDs of Group 2DF was significantly more than Group C (18.21\u2009\u00b1\u20093.40\u00a0days vs 16.14\u2009\u00b1\u20095.20\u00a0days, <jats:italic>P<\/jats:italic>\u2009=\u20090.001). Furthermore, the better life function score was achieved in Group 2DF according to FLIE questionnaire.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The administration of two-dose fosaprepitant was safe and more effective than one dose in protecting patients from CINV induced by three-day cisplatin included chemotherapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-024-05766-7","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T12:15:55Z","timestamp":1717589755000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Two doses of fosaprepitant included prophylactic treatment for the three-day cisplatin-based chemotherapy induced nausea and vomiting"],"prefix":"10.1007","volume":"150","author":[{"given":"Yanying","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuming","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingwei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangguo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,5]]},"reference":[{"key":"5766_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jnci.2017.05.001","volume":"29","author":"R Abdel-Malek","year":"2017","unstructured":"Abdel-Malek R, Abbas N, Shohdy KS et al (2017) Addition of 3-day aprepitant to ondansetron and dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting among patients with diffuse large B cell lymphoma receiving 5-day cisplatin-based chemotherapy. J Egypt Natl Canc Inst 29:155\u2013158","journal-title":"J Egypt Natl Canc Inst"},{"key":"5766_CR2","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1200\/JCO.2011.39.5558","volume":"30","author":"C Albany","year":"2012","unstructured":"Albany C, Brames MJ, Fausel C, Johnson CS, Picus J, Einhorn LH (2012) Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study. J Clin Oncol 30:3998\u20134003","journal-title":"J Clin Oncol"},{"key":"5766_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jama.2017.7156","volume":"318","author":"E Basch","year":"2017","unstructured":"Basch E, Deal AM, Dueck AC et al (2017) overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA 318:197\u2013198","journal-title":"JAMA"},{"key":"5766_CR5","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lungcan.2009.05.018","volume":"68","author":"K Funai","year":"2010","unstructured":"Funai K, Takamochi K, Itaya T et al (2010) Feasibility study of adjuvant chemotherapy with gemcitabine and split-dose cisplatin for completely resected non-small-cell lung cancer. Lung Cancer 68:78\u201383","journal-title":"Lung Cancer"},{"key":"5766_CR6","first-page":"259","volume":"36","author":"K Furugaki","year":"2009","unstructured":"Furugaki K, Yoshida J, Ogawa R et al (2009) Chemotherapy for non-small cell lung cancer: split-dose administration of Cisplatin over four consecutive days and Vinorelbine ditartrate. Gan to Kagaku Ryoho Cancer & Chemother 36:259\u2013263","journal-title":"Gan to Kagaku Ryoho Cancer & Chemother"},{"key":"5766_CR7","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1186\/s12885-023-11070-3","volume":"23","author":"A Gao","year":"2023","unstructured":"Gao A, Guan S, Sun Y et al (2023) Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy. BMC Cancer 23:609","journal-title":"BMC Cancer"},{"key":"5766_CR8","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1200\/JCO.2010.31.7859","volume":"29","author":"S Grunberg","year":"2011","unstructured":"Grunberg S, Chua D, Maru A et al (2011) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol\u2013EASE. J Clin Oncol 29:1495\u20131501","journal-title":"J Clin Oncol"},{"key":"5766_CR9","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","volume":"21","author":"H Hashimoto","year":"2020","unstructured":"Hashimoto H, Abe M, Tokuyama O et al (2020) Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21:242\u2013249","journal-title":"Lancet Oncol"},{"key":"5766_CR10","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1200\/JCO.21.01315","volume":"40","author":"A Hata","year":"2022","unstructured":"Hata A, Okamoto I, Inui N et al (2022) Randomized, double-blind, phase III study of fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting: CONSOLE. J Clin Oncol 40:180\u2013188","journal-title":"J Clin Oncol"},{"key":"5766_CR11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00520-016-3332-x","volume":"25","author":"K Jordan","year":"2017","unstructured":"Jordan K, Chan A, Gralla RJ et al (2017) 2016 Updated MASCC\/ESMO consensus recommendations: emetic risk classification and evaluation of the emetogenicity of antineoplastic agents. Support Care Cancer 25:271\u2013275","journal-title":"Support Care Cancer"},{"key":"5766_CR12","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1080\/16078454.2021.2001150","volume":"26","author":"T Kamiya","year":"2021","unstructured":"Kamiya T, Sakurai M, Kikuchi T et al (2021) Efficacy of ondansetron against emesis induced by a multiple-day cisplatin-based chemotherapy regimen for malignant lymphoma. Hematology 26:945\u2013949","journal-title":"Hematology"},{"key":"5766_CR13","doi-asserted-by":"publisher","first-page":"5493","DOI":"10.1200\/JCO.2006.08.7882","volume":"24","author":"GV Kondagunta","year":"2006","unstructured":"Kondagunta GV, Motzer RJ (2006) Chemotherapy for advanced germ cell tumors. J Clin Oncol 24:5493\u20135502","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"5766_CR14","first-page":"S39","volume":"26","author":"Y Li","year":"2018","unstructured":"Li Y, Qin Y, Yang L, Wang Y, Zhu J (2018) The CINV caused by multiple-day cisplatin-based highly emetogenic chemotherapy can last a long period of time in patients with NSCLC. Support Care Cancer 26(Suppl 2):S39-364","journal-title":"Support Care Cancer"},{"key":"5766_CR15","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.2217\/fon-2021-1523","volume":"18","author":"Y Li","year":"2022","unstructured":"Li Y, Sun Y, Liu B et al (2022) Prolonged administration of aprepitant improves cisplatin-based chemotherapy-induced nausea and vomiting. Future Oncol 18:2533\u20132543","journal-title":"Future Oncol"},{"key":"5766_CR16","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1007\/s00520-012-1696-0","volume":"21","author":"IN Olver","year":"2013","unstructured":"Olver IN, Grimison P, Chatfield M et al (2013) Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy. Support Care Cancer 21:1561\u20131568","journal-title":"Support Care Cancer"},{"key":"5766_CR17","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/943618","volume":"2015","author":"P Ranganath","year":"2015","unstructured":"Ranganath P, Einhorn L, Albany C (2015) Management of chemotherapy induced nausea and vomiting in patients on multiday cisplatin based combination chemotherapy. Biomed Res Int 2015:943618","journal-title":"Biomed Res Int"},{"key":"5766_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00520-018-4464-y","volume":"27","author":"Y Razvi","year":"2019","unstructured":"Razvi Y, Chan S, McFarlane T et al (2019) ASCO, NCCN, MASCC\/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. Support Care Cancer 27:87\u201395","journal-title":"Support Care Cancer"},{"key":"5766_CR19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/nrclinonc.2014.225","volume":"12","author":"R Rosell","year":"2015","unstructured":"Rosell R, Karachaliou N (2015) Lung cancer in 2014: optimizing lung cancer treatment approaches. Nat Rev Clin Oncol 12:75\u201376","journal-title":"Nat Rev Clin Oncol"},{"key":"5766_CR20","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.2217\/cer-2018-0089","volume":"7","author":"LS Schwartzberg","year":"2018","unstructured":"Schwartzberg LS, McLaughlin T, Geller RB, Gabrail NY, Marks SM (2018) Real-world efficacy: intravenous palonosetron three-drug regimen for chemotherapy-induced nausea and vomiting with highly emetogenic chemotherapy. J Comp Effect Res 7:1161\u20131170","journal-title":"J Comp Effect Res"},{"key":"5766_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.critrevonc.2015.12.001","volume":"99","author":"S Sommariva","year":"2016","unstructured":"Sommariva S, Pongiglione B, Tarricone R (2016) Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review. Crit Rev Oncol Hematol 99:13\u201336","journal-title":"Crit Rev Oncol Hematol"},{"key":"5766_CR22","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1007\/s00432-021-03554-1","volume":"147","author":"Y Sun","year":"2021","unstructured":"Sun Y, Zheng Y, Yang X et al (2021) Incidence of chemotherapy-induced nausea and vomiting among cancer patients receiving moderately to highly emetogenic chemotherapy in cancer centers in Sichuan, China. J Cancer Res Clin Oncol 147:2701\u20132708","journal-title":"J Cancer Res Clin Oncol"},{"key":"5766_CR23","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1089\/jicm.2022.0672","volume":"29","author":"H Wei","year":"2023","unstructured":"Wei H, Sun Y, Xie L et al (2023) Huo Xiang Zheng Qi Oral liquid combined with 5-HT3 receptor antagonists and dexamethasone can prevent chemotherapy-induced nausea and vomiting for patients receiving multiday cisplatin-based regimen: a multicenter trial. J Integr Complement Med 29:501\u2013509","journal-title":"J Integr Complement Med"},{"key":"5766_CR24","doi-asserted-by":"publisher","first-page":"e913","DOI":"10.1016\/j.cllc.2018.08.006","volume":"19","author":"F Wu","year":"2018","unstructured":"Wu F, Lin X, Yang Z et al (2018) Phase III randomized trial of palonosetron and dexamethasone with or without aprepitant to prevent nausea and vomiting induced by full-dose single-day cisplatin-based chemotherapy in lung cancer. Clin Lung Cancer 19:e913-918","journal-title":"Clin Lung Cancer"},{"issue":"6","key":"5766_CR25","doi-asserted-by":"publisher","first-page":"e12668","DOI":"10.1111\/ecc.12668","volume":"26","author":"LQ Yang","year":"2017","unstructured":"Yang LQ, Sun XC, Qin SK et al (2017) Efficacy and safety of fosaprepitant in the prevention of nausea and vomiting following highly emetogenic chemotherapy in Chinese people: A randomized, double-blind, phase III study. Eur J Cancer Care (engl). 26(6):e12668","journal-title":"Eur J Cancer Care (engl)."},{"key":"5766_CR26","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1158\/1055-9965.EPI-18-0569","volume":"28","author":"D Yuwen","year":"2019","unstructured":"Yuwen D, Ma Y, Wang D et al (2019) Prognostic role of circulating exosomal miR-425-3p for the response of NSCLC to platinum-based chemotherapy. Cancer Epidemiol Biomarkers Prev 28:163\u2013173","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"5766_CR27","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1093\/annonc\/mdx698","volume":"29","author":"L Zhang","year":"2018","unstructured":"Zhang L, Lu S, Feng J et al (2018) A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Ann Oncol 29:452\u2013458","journal-title":"Ann Oncol"},{"key":"5766_CR28","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s10549-020-05730-2","volume":"182","author":"J Zhang","year":"2020","unstructured":"Zhang J, Lin M, Jin Y et al (2020) Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia. Breast Cancer Res Treat 182:719\u2013726","journal-title":"Breast Cancer Res Treat"},{"key":"5766_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101771","volume":"55","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Yang Y, Gao F et al (2023) A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study). EClinicalMedicine 55:101771","journal-title":"EClinicalMedicine"},{"key":"5766_CR30","unstructured":"Zhu J, Li Y, Luo Y, Qin Y, Yang L, Wang Y (2018) The CINV caused by multiple-day cisplatin-based highly emetogenic chemotherapy can last a long period of time in patientswith nsclc. Supportive Care Cancer. In: MASCC\/ISOO conference abstract,2018 eP022"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05766-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-024-05766-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05766-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T10:51:56Z","timestamp":1720522316000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-024-05766-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["5766"],"URL":"https:\/\/doi.org\/10.1007\/s00432-024-05766-7","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,5]]},"assertion":[{"value":"25 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the ethics committee of West China Hospital of Sichuan University. We also obtained verbal and written informed consent from the patients to include their medical and treatment history in this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical disclosures statement"}}],"article-number":"290"}}